EU antitrust regulators to decide on Novartis, GSK deals by Jan 14 - (Yahoo!7 News via NewsPoints Desk)

  • EU antitrust authorities are expected to render a decision on whether to clear an asset swap between GlaxoSmithKline and Novartis by January 14, as reported Yahoo!7 News Monday.
  • In the deal, Novartis is buying GlaxoSmithKline's oncology products for $14.5 billion plus up to $1.5 billion based on the results of a trial in melanoma, while GlaxoSmithKline is purchasing Novartis' vaccines business, excluding influenza, for about $5.3 billion plus potential milestone payments of up to $1.8 billion and ongoing royalties.
  • The drugmakers are also planning a joint venture in consumer healthcare.
  • The European Commission can approve the deal, demand concessions or open an investigation into the matter.

To read more NewsPoints articles, click here.